Show simple item record

dc.contributor.authorBronchud, M
dc.contributor.authorScarffe, J Howard
dc.contributor.authorThatcher, Nick
dc.contributor.authorCrowther, Derek
dc.contributor.authorSouza, L M
dc.contributor.authorAlton, N K
dc.contributor.authorTesta, Nydia G
dc.contributor.authorDexter, T Michael
dc.date.accessioned2010-07-21T16:19:51Z
dc.date.available2010-07-21T16:19:51Z
dc.date.issued1988-08
dc.identifier.citationPhase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. 1988 (83):327-9 Behring Inst. Mitt.en
dc.identifier.issn0301-0457
dc.identifier.pmid2467655
dc.identifier.urihttp://hdl.handle.net/10541/108118
dc.description.abstractTwelve patients with advanced small cell carcinoma of the bronchus were treated by continuous infusion of recombinant human granulocyte colony-stimulating factor (rh G-CSF) at the following dose levels: 1 microgram, 5 micrograms, 10 micrograms, 20 micrograms and 40 micrograms/kg/day for 5 days. No toxicities resulted from the treatment and in all 12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100 x 10(9)/l in one patient at 10 micrograms/kg/day. The neutrophils were shown to be functionally normal in tests of their mobility and bactericidal activity. During the Phase II part of the patients were treated using a combination of i.v. Adriamycin, Ifosfamide and Etoposide. The chemotherapy was repeated every 3 weeks. rh G-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal, neutrophil counts within 2 weeks after day 1 of chemotherapy. Ten severe infective episodes were observed during the 20 cycles of chemotherapy which did not include rh G-CSF, while only one infective episode occurred in 20 courses when treated with rh G-CSF. These results demonstrate the utility of rh G-CSF in restoring functional neutrophils to patients undergoing intensive chemotherapy.
dc.language.isoenen
dc.subjectHaemoglobinen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshColony-Stimulating Factors
dc.subject.meshDoxorubicin
dc.subject.meshDrug Evaluation
dc.subject.meshEtoposide
dc.subject.meshGranulocyte Colony-Stimulating Factor
dc.subject.meshHemoglobins
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshLeukocyte Count
dc.subject.meshLung Neoplasms
dc.subject.meshMesna
dc.subject.meshNeutrophils
dc.subject.meshPlatelet Count
dc.subject.meshRecombinant Proteins
dc.titlePhase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalBehring Institute Mitteilungenen
html.description.abstractTwelve patients with advanced small cell carcinoma of the bronchus were treated by continuous infusion of recombinant human granulocyte colony-stimulating factor (rh G-CSF) at the following dose levels: 1 microgram, 5 micrograms, 10 micrograms, 20 micrograms and 40 micrograms/kg/day for 5 days. No toxicities resulted from the treatment and in all 12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100 x 10(9)/l in one patient at 10 micrograms/kg/day. The neutrophils were shown to be functionally normal in tests of their mobility and bactericidal activity. During the Phase II part of the patients were treated using a combination of i.v. Adriamycin, Ifosfamide and Etoposide. The chemotherapy was repeated every 3 weeks. rh G-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal, neutrophil counts within 2 weeks after day 1 of chemotherapy. Ten severe infective episodes were observed during the 20 cycles of chemotherapy which did not include rh G-CSF, while only one infective episode occurred in 20 courses when treated with rh G-CSF. These results demonstrate the utility of rh G-CSF in restoring functional neutrophils to patients undergoing intensive chemotherapy.


This item appears in the following Collection(s)

Show simple item record